| Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000. | |
| | |
MedLine Citation:
|
PMID: 12635465 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Between 1986 and 2000 183 Austrian children and adolescents with non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-ALL) were enrolled in 3 consecutive studies of the Berlin-Frankfurt-Münster (BFM) Group. In trial NHL-BFM 86, patients were stratified according to the histologic subtype and clinical stage. In the succeeding studies NHL-BFM 90 and 95, treatment stratification was additionally based on the speed of tumor response to therapy and for children with B-cell NHL/B-ALL also on the pre-therapeutic serum lactic dehydrogenase level. Event-free survival rates were 84% +/- 6% in trial NHL-BFM 86 (n = 39) and 86% +/- 4% in both trials NHL-BFM 90 (n = 67) and NHL-BFM 95 (n = 77). Patients with lymphoblastic lymphoma (mainly with T-cell phenotypes) had an excellent prognosis with an ALL-type chemotherapy regimen (n = 49; relapse, n = 1), whereas an intensive, short-pulse therapy delivered within a 2- to 4-month period was found to be highly efficacious in children with B-cell NHL/B-ALL (n = 114; relapse, n = 6; progression, n = 5). Patients with anaplastic large cell lymphoma (ALCL) who were treated with similar alternating short courses of multi-agent chemotherapy had a less good outcome (n = 20; relapse, n = 6, progression, n = 3). Children with B-cell NHL and B-ALL who failed initial therapy also had a dismal prognosis (10/11 patients died). Local radiotherapy as a part of lymphoma therapy was completely abandoned in study NHL-BFM 90 and surgical interventions were confined to specific situations such as complete resection in localized B-cell NHL and ALCL, diagnostic biopsy and second-look operation. In conclusion, our results showed that the BFM treatment strategy for lymphoblastic lymphoma and B-cell NHL/B-ALL was highly successful in the majority of patients; however, optimal treatment for children with ALCL has not yet been defined. As a consequence, larger trials at an international level are necessary to find new prognostic markers that might define more precisely those patients who need further intensification of first-line treatment or novel therapy. |
| | |
Authors:
|
Andishe Attarbaschi; Georg Mann; Michael Dworzak; Monika Trebo; Christian Urban; Franz-Martin Fink; Ernst Horcher; Alfred Reiter; Hansjörg Riehm; Helmut Gadner; |
Related Documents
:
|
11205715 - Etiology of stroke in children. 17197975 - Asymptomatic cholelithiasis in children with sickle cell disease: early or delayed chol... 19055665 - Longitudinal follow up of elevated pulmonary artery pressures in children with sickle c... 1714695 - Glomerular filtration rate in healthy nigerian children and in children with sickle cel... 12717485 - How much do parents know about their children's heart condition and prophylaxis against... 11564125 - Use of levetiracetam in special populations. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study |
Journal Detail:
|
Title: Wiener klinische Wochenschrift Volume: 114 ISSN: 0043-5325 ISO Abbreviation: Wien. Klin. Wochenschr. Publication Date: 2002 Dec |
Date Detail:
|
Created Date: 2003-03-14 Completed Date: 2003-05-19 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 21620870R Medline TA: Wien Klin Wochenschr Country: Austria |
Other Details:
|
Languages: eng Pagination: 978-86 Citation Subset: IM |
Affiliation:
|
St. Anna Children's Hospital, Vienna, Austria. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Antineoplastic Agents / administration & dosage, therapeutic use Burkitt Lymphoma / diagnosis, drug therapy, mortality, therapy* Child Child, Preschool Data Interpretation, Statistical Disease-Free Survival Female Follow-Up Studies Humans Infant Lymphoma, B-Cell / diagnosis, drug therapy, mortality, therapy Lymphoma, Non-Hodgkin / diagnosis, drug therapy, mortality, therapy* Male Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis, drug therapy, mortality, therapy Prognosis Prospective Studies Risk Factors Survival Analysis Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Anti chlamydia antibodies in patients with thoracic and abdominal aortic aneurysms.
Next Document: Correlation of lipoprotein(a) levels and myocardial stress thallium scintigraphy pattern in differen...